Bethany A Dale
Novartis
2 Papers
74 Citations
Bethany A Dale is an academic researcher from Novartis. The author has contributed to research in topics: Binding site & Glycogen. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.
Robert A. Pearlstein,Qi-Ying Hu,Jing Zhou,David Yowe,Julian Levell,Bethany A Dale,Virendar K. Kaushik,Douglas S. Daniels,Susan Hanrahan,Woody Sherman,Robert Abel +10 more
TL;DR: It is proposed that the fast kon and entropically driven thermodynamics observed for PCSK9‐EGF‐A binding stem from the functional replacement of water occupying stable PCSK 9 hydration sites, and that the relatively fast koff observed for EGF‐A unbinding stems from the limited displacement of solvent occupying unstable hydration Sites.
81
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.
Gregory Raymond Bebernitz,Valerie Beaulieu,Bethany A Dale,Richard Deacon,Alokesh Duttaroy,Jiaping Gao,Melissa S. Grondine,Ramesh Chandra Gupta,Mesut Kakmak,Michael Kavana,Louise Kirman,Jinsheng Liang,Wieslawa Maniara,Siralee Munshi,Sunil Sadanand Nadkarni,Herbert F. Schuster,Travis Stams,Irene St. Denny,Paul Taslimi,Brian Edward Vash,Shari L. Caplan +20 more
TL;DR: Efforts on a sulfonamide chemotype with the aim to generate liver selective GK activators which culminated in the discovery of 3-cyclopentyl-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-2-[4-methyl-piperazine-1-sulfonyl)-phenyl]-propionamide (17c).